Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study
Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1996 |
|---|
| Umfang: |
7 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Annals of hematology - 1955, 72(1996) vom: Apr., Seite 216-222 |
| Übergeordnetes Werk: |
volume:72 ; year:1996 ; month:04 ; pages:216-222 ; extent:7 |
| Links: |
|---|
| Katalog-ID: |
NLEJ202978133 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ202978133 | ||
| 003 | DE-627 | ||
| 005 | 20210706114156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1996 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ202978133 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study |
| 264 | 1 | |c 1996 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Thalhammer, F. |4 oth | |
| 700 | 1 | |a Geissler, K. |4 oth | |
| 700 | 1 | |a Jäger, U. |4 oth | |
| 700 | 1 | |a Kyrle, P. A. |4 oth | |
| 700 | 1 | |a Pabinger, I. |4 oth | |
| 700 | 1 | |a Mitterbauer, M. |4 oth | |
| 700 | 1 | |a Gisslinger, H. |4 oth | |
| 700 | 1 | |a Knöbl, P. |4 oth | |
| 700 | 1 | |a Laczika, K. |4 oth | |
| 700 | 1 | |a Schneider, B. |4 oth | |
| 700 | 1 | |a Haas, O. A. |4 oth | |
| 700 | 1 | |a Lechner, K. |4 oth | |
| 773 | 0 | 8 | |i in |t Annals of hematology |d 1955 |g 72(1996) vom: Apr., Seite 216-222 |w (DE-627)NLEJ18898836X |w (DE-600)1458429-3 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:1996 |g month:04 |g pages:216-222 |g extent:7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s002770050163 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 1996 |c 4 |h 216-222 |g 7 | ||
| matchkey_str |
article:14320584:1996----::uainfeodopeeeisoiptetwtaueylilueitetdihhmteay |
|---|---|
| hierarchy_sort_str |
1996 |
| publishDate |
1996 |
| allfields |
(DE-627)NLEJ202978133 DE-627 ger DE-627 rakwb eng Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study 1996 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR. Springer Online Journal Archives 1860-2002 Thalhammer, F. oth Geissler, K. oth Jäger, U. oth Kyrle, P. A. oth Pabinger, I. oth Mitterbauer, M. oth Gisslinger, H. oth Knöbl, P. oth Laczika, K. oth Schneider, B. oth Haas, O. A. oth Lechner, K. oth in Annals of hematology 1955 72(1996) vom: Apr., Seite 216-222 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:72 year:1996 month:04 pages:216-222 extent:7 http://dx.doi.org/10.1007/s002770050163 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 72 1996 4 216-222 7 |
| spelling |
(DE-627)NLEJ202978133 DE-627 ger DE-627 rakwb eng Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study 1996 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR. Springer Online Journal Archives 1860-2002 Thalhammer, F. oth Geissler, K. oth Jäger, U. oth Kyrle, P. A. oth Pabinger, I. oth Mitterbauer, M. oth Gisslinger, H. oth Knöbl, P. oth Laczika, K. oth Schneider, B. oth Haas, O. A. oth Lechner, K. oth in Annals of hematology 1955 72(1996) vom: Apr., Seite 216-222 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:72 year:1996 month:04 pages:216-222 extent:7 http://dx.doi.org/10.1007/s002770050163 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 72 1996 4 216-222 7 |
| allfields_unstemmed |
(DE-627)NLEJ202978133 DE-627 ger DE-627 rakwb eng Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study 1996 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR. Springer Online Journal Archives 1860-2002 Thalhammer, F. oth Geissler, K. oth Jäger, U. oth Kyrle, P. A. oth Pabinger, I. oth Mitterbauer, M. oth Gisslinger, H. oth Knöbl, P. oth Laczika, K. oth Schneider, B. oth Haas, O. A. oth Lechner, K. oth in Annals of hematology 1955 72(1996) vom: Apr., Seite 216-222 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:72 year:1996 month:04 pages:216-222 extent:7 http://dx.doi.org/10.1007/s002770050163 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 72 1996 4 216-222 7 |
| allfieldsGer |
(DE-627)NLEJ202978133 DE-627 ger DE-627 rakwb eng Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study 1996 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR. Springer Online Journal Archives 1860-2002 Thalhammer, F. oth Geissler, K. oth Jäger, U. oth Kyrle, P. A. oth Pabinger, I. oth Mitterbauer, M. oth Gisslinger, H. oth Knöbl, P. oth Laczika, K. oth Schneider, B. oth Haas, O. A. oth Lechner, K. oth in Annals of hematology 1955 72(1996) vom: Apr., Seite 216-222 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:72 year:1996 month:04 pages:216-222 extent:7 http://dx.doi.org/10.1007/s002770050163 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 72 1996 4 216-222 7 |
| allfieldsSound |
(DE-627)NLEJ202978133 DE-627 ger DE-627 rakwb eng Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study 1996 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR. Springer Online Journal Archives 1860-2002 Thalhammer, F. oth Geissler, K. oth Jäger, U. oth Kyrle, P. A. oth Pabinger, I. oth Mitterbauer, M. oth Gisslinger, H. oth Knöbl, P. oth Laczika, K. oth Schneider, B. oth Haas, O. A. oth Lechner, K. oth in Annals of hematology 1955 72(1996) vom: Apr., Seite 216-222 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:72 year:1996 month:04 pages:216-222 extent:7 http://dx.doi.org/10.1007/s002770050163 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 72 1996 4 216-222 7 |
| language |
English |
| source |
in Annals of hematology 72(1996) vom: Apr., Seite 216-222 volume:72 year:1996 month:04 pages:216-222 extent:7 |
| sourceStr |
in Annals of hematology 72(1996) vom: Apr., Seite 216-222 volume:72 year:1996 month:04 pages:216-222 extent:7 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Annals of hematology |
| authorswithroles_txt_mv |
Thalhammer, F. @@oth@@ Geissler, K. @@oth@@ Jäger, U. @@oth@@ Kyrle, P. A. @@oth@@ Pabinger, I. @@oth@@ Mitterbauer, M. @@oth@@ Gisslinger, H. @@oth@@ Knöbl, P. @@oth@@ Laczika, K. @@oth@@ Schneider, B. @@oth@@ Haas, O. A. @@oth@@ Lechner, K. @@oth@@ |
| publishDateDaySort_date |
1996-04-01T00:00:00Z |
| hierarchy_top_id |
NLEJ18898836X |
| id |
NLEJ202978133 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202978133</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706114156.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1996 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202978133</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thalhammer, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Geissler, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jäger, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kyrle, P. A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pabinger, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mitterbauer, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gisslinger, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Knöbl, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laczika, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schneider, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haas, O. A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lechner, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">72(1996) vom: Apr., Seite 216-222</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:72</subfield><subfield code="g">year:1996</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:216-222</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s002770050163</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">72</subfield><subfield code="j">1996</subfield><subfield code="c">4</subfield><subfield code="h">216-222</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ18898836X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-0584 |
| topic_title |
Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
f t ft k g kg u j uj p a k pa pak i p ip m m mm h g hg p k pk k l kl b s bs o a h oa oah k l kl |
| hierarchy_parent_title |
Annals of hematology |
| hierarchy_parent_id |
NLEJ18898836X |
| hierarchy_top_title |
Annals of hematology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ18898836X (DE-600)1458429-3 |
| title |
Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study |
| spellingShingle |
Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study |
| ctrlnum |
(DE-627)NLEJ202978133 |
| title_full |
Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study |
| journal |
Annals of hematology |
| journalStr |
Annals of hematology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1996 |
| contenttype_str_mv |
zzz |
| container_start_page |
216 |
| container_volume |
72 |
| physical |
7 |
| format_se |
Elektronische Aufsätze |
| title_sort |
duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study |
| title_auth |
Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study |
| abstract |
Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR. |
| abstractGer |
Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR. |
| abstract_unstemmed |
Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study |
| url |
http://dx.doi.org/10.1007/s002770050163 |
| remote_bool |
true |
| author2 |
Thalhammer, F. Geissler, K. Jäger, U. Kyrle, P. A. Pabinger, I. Mitterbauer, M. Gisslinger, H. Knöbl, P. Laczika, K. Schneider, B. Haas, O. A. Lechner, K. |
| author2Str |
Thalhammer, F. Geissler, K. Jäger, U. Kyrle, P. A. Pabinger, I. Mitterbauer, M. Gisslinger, H. Knöbl, P. Laczika, K. Schneider, B. Haas, O. A. Lechner, K. |
| ppnlink |
NLEJ18898836X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth |
| up_date |
2024-07-06T09:26:26.039Z |
| _version_ |
1803821237969879040 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202978133</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706114156.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1996 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202978133</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p=0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of >12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievment of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the supression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thalhammer, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Geissler, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jäger, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kyrle, P. A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pabinger, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mitterbauer, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gisslinger, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Knöbl, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laczika, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schneider, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haas, O. A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lechner, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">72(1996) vom: Apr., Seite 216-222</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:72</subfield><subfield code="g">year:1996</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:216-222</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s002770050163</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">72</subfield><subfield code="j">1996</subfield><subfield code="c">4</subfield><subfield code="h">216-222</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| score |
7.3989916 |